Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing (Q46091045)

From Wikidata

Jump to navigation Jump to search

scientific article published in May 2012

Language	Label	Description	Also known as
English	Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing	scientific article published in May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

0 references

Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

pharmacokinetics

1 reference

based on heuristic

inferred from title

Jaap Jan Boelens

object named as

Jaap J Boelens

2

0 references

Meindert Danhof

11

object named as

Meindert Danhof

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Catherijne Knibbe

12

object named as

Catherijne A J Knibbe

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

author name string

Imke H Bartelink

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Robbert G M Bredius

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Antoine C G Egberts

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Chenguang Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Marc B Bierings

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Peter J Shaw

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Christa E Nath

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

George Hempel

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Juliette Zwaveling

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

51

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

331-345

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Busulfan in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Plasma concentration monitoring of busulfan: does it improve clinical outcome?

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Therapeutic drug monitoring of busulfan in transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Handling data below the limit of quantification in mixed effect models

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

NONMEMory: a run management tool for NONMEM.

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Diagnosing model diagnostics

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures.

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Morphine glucuronidation in preterm neonates, infants and children younger than 3 years

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Fludarabine and Once-Daily Intravenous Busulfan for Allogeneic Bone Marrow Transplantation for Chediak-Higashi Syndrome

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Mechanism-based concepts of size and maturity in pharmacokinetics

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen

1 reference

https://api.crossref.org/works/10.2165%2F11598180-000000000-00000

21 January 2018

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Up-regulation of glutathione S-transferase activity in enterocytes of young children

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Busulfan Dosing in Children with BMIs ≥85% Undergoing HSCT: A New Optimal Strategy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Busulfan bioavailability.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Busulfan disposition below the age of three: alteration in children with lysosomal storage disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoi

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22455797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11598180-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22455797

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46091045&oldid=2253388759"